Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Relapsed or refractory lymphoma (Grade 1, 2, 3A)~* Received 2 or more prior lines of systemic therapy for lymphoma~* Experienced glucose \>250 mg/dL after copanlisib infusion for treatment of lymphoma~Exclusion Criteria:~* Evidence of histologic transformation~* Follicular Lymphoma Grade 3B~* Active CNS involvement by malignancy~* Elevated AST or ALT \> 5x ULN at Screening~* Unmanageable sensitivity to mammalian-derived drug preparations, or to humanized or human antibodies; managed sensitivities to agents such as obinutuzumab or rituximab or similar agents are not exclusionary~* History of drug or alcohol abuse within the last 6 months~* History or family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia~* History or family history of pheochromocytoma~* Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness) conditions specific to diabetes that would pose additional risk to subject's safety or interfere with the study evaluation, procedures or completion in the opinion of the treating physician.~* Female subject is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REMD-477 (Type: EXPERIMENTAL): REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses

Based on this trial design, predict the completion outcome and termination type (if applicable).